Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum YM BioSciences Inc YMI

Bullboard (NYSEAM:YMI)

View:
Post by insiderinfocanon Oct 29, 2009 5:58pm

Good News

YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG PRNewsWire News Releases Published:10/29/09 05:30 PM EDT ...more  
Post by greatemailslobon Oct 27, 2009 2:23pm

looking to rebuy under a buck

and then sell in janaury for a doublewatch and learn ladies
Post by Numb3rson Oct 05, 2009 7:10pm

YM BioSciences plans to acquire Cytopia

YM BioSciences plans to acquire Cytopia2009-10-05 18:58 ET - News Release Mr. David Allan reportsYM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD., AN AUSTRALIAN CANCER-FOCUSED DEVELOPMENT ...more  
Post by gerardtvon Sep 28, 2009 2:57pm

update YM vs ISA Comparasion But Why ??

Google News Alert for: ISOTECHNIKA INC
Post by chuck8on Sep 27, 2009 8:26pm

What's next?

Any ideas on road map and what might lay ahead of us? Eventual FDA approval of course would be something we all hope will happen but time frame guesses? Also, analyst coverage and rec of $5 is a nice ...more  
Comment by DutchGoldMineon Sep 18, 2009 4:13am

RE: $40 Million in Cash

With 56 million shares out it is more or less  0.70 cents cash a share. Still a good number.
Comment by redcoatson Sep 18, 2009 12:27am

RE: $40 Million in Cash

How sweet it is.
Post by JuniorIOUon Sep 17, 2009 10:29am

$40 Million in Cash

$2.00 Now trading at cash value :)
Post by MIA17on Sep 17, 2009 8:52am

Approved in Mexico

$0$0YM Biosciences receives nimotuzumab approval in Mexico$0$0$0$0$02009-09-17 08:21 ET - News Release$0$0Mr. David Allan reports$0$0YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING ...more  
Post by DutchGoldMineon Sep 15, 2009 8:58am

good analyses on nimotuzumab

A lot of attention in this blog for nimotuzumab. Good reading. https://www.gekkowire.com/
Comment by DutchGoldMineon Sep 07, 2009 5:31pm

RE: Efficacy

come on DYOR for instance look at the news release of 6/23/2009 and you find this:Results were reported recently at the 2009 ASCO Annual Meeting from arandomized Phase IIb, four-arm, open-label trial ...more  
Post by ahnunahon Sep 07, 2009 10:42am

Efficacy

Forgive me if this has been discussed previously on the boards:On TheStreet.com, Aug. 14 it was said that thus far, the data has shown that Nimotuzumab doesn't have the efficacy of it's ...more  
Comment by The_Shadowon Sep 03, 2009 12:14pm

RE: gaps

So the SLOB now claims to have sold his ''free'' shares - the 20000 he left on the table last week.BUT the SLOB makes this report of his sale SEVERAL DAYS after the fact!Very credible ...more  
Comment by greatemailslobon Sep 02, 2009 9:34pm

RE: gaps

thedave i am completely outa double on 40000 shares average cost 110gain 36000LOVIN YOUR FOLLOWING
Post by thedave2006on Sep 01, 2009 9:09pm

gaps

closes one way or the other depending on the momentum....no surprises, history dictates it almost 100% of the time.dave.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities